Skip to main content

Table 3 Comparison of other genetic alterations between older and younger AML patients a

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Variant Number of patients with the gene mutation (percentage); Median of RNA expression (delta CT) P
Whole cohort 60 years or younger, (n=69) Older than 60 y/o, (n=44)
NPM1 mut 38 (33.33%) 21 (30%) 17 (38.64%) 0.227
FLT3- ITD 23 (20.18%) 15 (21/43%) 8 (18.18%) 0.433
FLT3- TKD 8 (7.02%) 2 (2.86%) 6 (13.64%) 0.036*
NPM1mut/FLT3- ITDneg 22 (19.30%) 11(15.71%) 11 (25%) 0.164
CEBPA a 34 (30.36%) 18 (26.09%) 16 (37.20%) 0.151
CEBPA Double mutation,b 9 (78.04%) 8 (11.59%) 1 (2.23%) 0.016*
IDH1 c 3 (3.75 %) 2 (4%) 1 (3.3%) 0.686
IDH2 c 8 (10 %) 4 (8%) 4 (13.2%) 0.454
DNMT3A c 12 (15 %) 10 (25.641%) 2 (4.88%) 0.095
MLL 7 (8.75%) 4 (8%) 3 (10%) 0.528
Delta BDH2 d 9.006 (4.53-12.36) 9.051 (4.53-12.36) 8.915 (6.4-12.15) 0.102
ERG d 10.595 (4.52-19.92) 10.88 (5.17-19.92) 9.74 (4.52-19.85) 0.435
MN1 d 13.25 (7.75-19.87) 13.06 (7.76-19.87) 13.25 (7.75-18.38) 0.992
miR-181a d 3.21 (−3.8-8.44) 3.3 (−0.03-8.44) 2.49 (−3.8-8.2) 0.140
miR-3151 d 12.685 (4.97-15.29) 12.685 (9.16-15.07) 12.6 (4.97-15.29) 0.247
  1. Values are number (%) of patients with alteration.
  2. aCEBPAsingle and double mutations.
  3. bCEBPAdouble mutationvs CEBPAsingle mutationvs no mutation.
  4. cOnly 80 patients with high quality of DNA to sequence; 50 patients are 60 y/o or younger patients and 30 patients are high expression.
  5. dMedian delta CT(range).
  6. *Statistically significant (P < 0.05).